Production of a Monoclonal Antibody Targeting the M Protein of MERS-CoV for Detection of MERS-CoV Using a Synthetic Peptide Epitope Formulated with a CpG-DNA-Liposome Complex
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Byoung Kwon | - |
dc.contributor.author | Lee, Su In | - |
dc.contributor.author | Bae, Joon-Yong | - |
dc.contributor.author | Park, Man-Seong | - |
dc.contributor.author | Lee, Younghee | - |
dc.contributor.author | Kwon, Hyung-Joo | - |
dc.date.accessioned | 2021-09-01T07:21:12Z | - |
dc.date.available | 2021-09-01T07:21:12Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2019-09 | - |
dc.identifier.issn | 1573-3149 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/62991 | - |
dc.description.abstract | The Middle East respiratory syndrome-related coronavirus (MERS-CoV) contains four major structural proteins, the spike glycoprotein, nucleocapsid phosphoprotein, membrane (M) glycoprotein and small envelope glycoprotein. The M protein of MERS-CoV has a role in the morphogenesis or assembly of the virus and inhibits type I interferon expression in infected cells. Here, we produced a monoclonal antibody specific against the M protein of MERS-CoV by injecting BALB/c mice with a complex containing the epitope peptide and CpG-DNA encapsulated with a phosphatidyl-beta-oleoyl-gamma-palmitoyl ethanolamine (DOPE):cholesterol hemisuccinate (CHEMS). The monoclonal antibody was reactive to the epitope peptide of the M protein of MERS-CoV which was confirmed by western blotting and immunoprecipitations. Indirect immunofluorescence assay and confocal image analysis showed that the monoclonal antibody binds specifically to the M protein of MERS-CoV in the virus-infected cells. Further studies using this monoclonal antibody may provide important information on the function of the M protein and its future application in diagnostics. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.subject | RECEPTOR-BINDING DOMAIN | - |
dc.subject | CORONAVIRUS | - |
dc.subject | INHIBITION | - |
dc.subject | SARS | - |
dc.title | Production of a Monoclonal Antibody Targeting the M Protein of MERS-CoV for Detection of MERS-CoV Using a Synthetic Peptide Epitope Formulated with a CpG-DNA-Liposome Complex | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Man-Seong | - |
dc.identifier.doi | 10.1007/s10989-018-9731-8 | - |
dc.identifier.scopusid | 2-s2.0-85049598107 | - |
dc.identifier.wosid | 000479249600001 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS, v.25, no.3, pp.819 - 826 | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS | - |
dc.citation.title | INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS | - |
dc.citation.volume | 25 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 819 | - |
dc.citation.endPage | 826 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.subject.keywordPlus | RECEPTOR-BINDING DOMAIN | - |
dc.subject.keywordPlus | CORONAVIRUS | - |
dc.subject.keywordPlus | INHIBITION | - |
dc.subject.keywordPlus | SARS | - |
dc.subject.keywordAuthor | B cell epitope | - |
dc.subject.keywordAuthor | Monoclonal antibody | - |
dc.subject.keywordAuthor | MERS-CoV | - |
dc.subject.keywordAuthor | M protein | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.